<DOC>
	<DOCNO>NCT00082407</DOCNO>
	<brief_summary>This Phase 3 , multicenter , open-label , comparator-controlled trial compare effect exenatide twice daily twice daily biphasic insulin aspart glycemic control , measure hemoglobin A1c ( HbA1c ) .</brief_summary>
	<brief_title>Exenatide Compared With Twice-Daily Biphasic Insulin Aspart Patients With Type 2 Diabetes Using Sulfonylurea Metformin</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Biphasic Insulins</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<criteria>Patients treat stable dose follow least 3 month prior screen : 1 . &gt; =1500 mg/day immediaterelease metformin extendedrelease metformin least optimally effective dose brand sulfonylurea , 2. fixeddose sulfonylurea/metformin combination therapy sulfonylurea metformin requirement individual component HbA1c 7.0 % 11.0 % , inclusive . Patients body mass index &gt; 25kg/m2 &lt; 40 kg/m2 . Female patient breastfeed , female patient childbearing potential test negative pregnancy , intend become pregnant study , agree continue use reliable method birth control Patients investigator site personnel directly affiliate study , immediate family investigator site personnel directly affiliate study . Patients employ Lilly Amylin . Patients previously , study , receive exenatide glucagonlike peptide1 analog . Patients participate interventional medical , surgical , pharmaceutical study within 30 day prior screen . This criterion include drug receive regulatory approval indication time study entry . Patients great three episode severe hypoglycemia within 6 month prior screen . Patients le 5 year remission history malignancy ( basal cell squamous cell skin cancer , situ carcinoma cervix , situ prostate cancer ) . Patients cardiac disease Class III IV , accord New York Heart Association criterion . Patients know allergy hypersensitivity biphasic insulin aspart , exenatide , excipients contain agent . Patients characteristic contraindicate metformin sulfonylurea use , accord productspecific label . Patients history renal transplantation currently receive renal dialysis serum creatinine &gt; =1.5 mg/dL male &gt; =1.2 mg/dL female . Patients obvious clinical sign symptom liver disease , acute chronic hepatitis , alanine aminotransferase/serum glutamic pyruvic transaminase great three time upper limit reference range . Patients know hemoglobinopathy chronic anemia . Patients active proliferative retinopathy macular edema . Patients receive treatment gastrointestinal disease drug directly affect gastrointestinal motility , include limited metoclopramide , cisapride , chronic macrolide antibiotic . Patients receive chronic ( lasting longer 2 week ) systemic glucocorticoid therapy ( exclude topical inhale preparation ) receive therapy within 2 week immediately prior screening . Patients used prescription drug promote weight loss within 3 month prior screen . Patients treat longer 2 week follow excluded medication within 3 month prior screen : insulin , thiazolidinediones , alphaglucosidase inhibitor , meglitinides . Patients condition ( include know drug alcohol abuse psychiatric disorder ) preclude follow complete protocol , opinion investigator . Patients fail satisfy investigator suitability participate reason .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>diabetes</keyword>
	<keyword>exendin</keyword>
	<keyword>Amylin</keyword>
	<keyword>Lilly</keyword>
	<keyword>insulin aspart</keyword>
</DOC>